Inke Acquires Pharmanoid from Gentec Pharmaceutical Group

Keensight Capital Acquires Inke from Neuraxpharm

May 1, 2023

Pharmaceuticals

Keensight Capital has signed a binding agreement to acquire Inke, a Spain-based specialist developer and manufacturer of inhalation active pharmaceutical ingredients (APIs), from Neuraxpharm Group; financial terms were not disclosed and the deal is expected to close in May 2023. Neuraxpharm divested Inke to sharpen its focus on CNS therapies, while Keensight will support Inke's management team to expand its footprint, broaden its offering and grow its product portfolio.

Vistagen Acquires Pherin Pharmaceuticals

December 21, 2022

Biotechnology

Vistagen (Nasdaq: VTGN) will acquire Pherin Pharmaceuticals in an all-stock transaction (approximately 12.4 million shares plus nominal cash), giving Vistagen full ownership of Pherin's pherine drug pipeline and intellectual property. The deal eliminates future royalty and milestone obligations related to PH94B and PH10 and adds three early-stage pherine candidates to Vistagen's development portfolio.

ANJAC Health & Beauty Acquires Pillar5 Pharma

March 14, 2022

Pharmaceuticals

French family-owned ANJAC Health & Beauty has acquired Pillar5 Pharma, a Canadian CDMO specializing in sterile ophthalmic solutions and niche solid-dose manufacturing. The deal strengthens ANJAC's presence in North America and expands its pharmaceutical and ophthalmology capabilities; Pillar5 is based in Arnprior, Ontario and has roughly 150 employees and CAD$50M in revenue.

Olympus Partners Acquires PAI Pharma

February 24, 2025

Pharmaceuticals

Olympus Partners has acquired PAI Pharma, a leading U.S. developer, manufacturer and distributor of generic oral liquid medicines. The platform was previously owned by Enhanced Healthcare Partners and Bourne Partners Strategic Capital; terms were not disclosed and Monroe Capital provided senior financing for the deal.

Keensight Capital Agrees to Acquire Quanos Solutions from IK Partners

December 20, 2022

Software

Keensight Capital has signed an agreement to acquire Quanos Solutions GmbH from IK Partners' IK Small Cap II Fund. Quanos, headquartered in Nuremberg, Germany, is a provider of industrial aftersales and digital technical documentation software (around 270 employees and 1,000+ customers); Keensight will support the company’s next phase of growth, expanding its product suite, market penetration and international reach. Financial terms were not disclosed and the deal is subject to customary approvals.

Partners Group Acquires Pharmathen from BC Partners

July 19, 2021

Pharmaceuticals

Partners Group has agreed to acquire Pharmathen, the leading European drug delivery technology and pharmaceutical manufacturing company, from BC Partners in a transaction valued at approximately EUR 1.6 billion. The deal transfers control of Pharmathen to Partners Group (acting on behalf of its clients) and is aimed at supporting the company’s continued growth — including an intensified push into the US market — building on strong R&D and manufacturing capabilities.